Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
ApexOnco Front Page
Recent articles
PD-(L)1 x VEGF bispecifics prove a big draw.
The Avanzar study could read out shortly.
The company reckons its immunotherapy could improve on Keytruda.
Satri-cel is filed for gastric cancer approval in China.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
“We need all the capital we can get our hands on," the company states.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
